 |
|
D-Penicillamine in the Treatment of Localized Scleroderma
Vincent Falanga, MD;
Thomas A. Medsger, Jr, MD
Arch Dermatol. 1990;126(5):609-612.
Abstract
| |
• Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children. There is no accepted or proven treatment for localized scleroderma. Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article. This drug was judged to have a favorable effect on the disease course in 7 (64%) of 11 patients. Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients, skin softening in 5, and more normal growth of the affected limb in 2 of 3 children. Joint stiffness and contractures also improved. The dose of D-penicillamine associated with a favorable response was as low as 2 to 5 mg/kg per day given over a period ranging from 15 to 53 months. D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency. These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.
(Arch Dermatol. 1990;126:609-612)
Author Affiliations
From the Department of Dermatology and Cutaneous Surgery, University of Miami (Fla) School of Medicine (Dr Falanga) and Division of Rheumatology and Clinical Immunology, University of Pittsburgh (Pa) School of Medicine (Dr Medsger).
Footnotes
Accepted for publication August 15, 1989.
Reprint requests to Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, PO Box 016250 (R-250), Miami, FL 33101 (Dr Falanga).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil
Martini et al.
Rheumatology (Oxford) 2009;48:1410-1413.
ABSTRACT
| FULL TEXT
Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study
Zulian et al.
Rheumatology (Oxford) 2006;45:614-620.
ABSTRACT
| FULL TEXT
Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate in Severe Localized Scleroderma
Kreuter et al.
Arch Dermatol 2005;141:847-852.
ABSTRACT
| FULL TEXT
Narrative Review: Diseases That Masquerade as Infectious Cellulitis
Falagas and Vergidis
ANN INTERN MED 2005;142:47-55.
ABSTRACT
| FULL TEXT
Juvenile-onset localized scleroderma activity detection by infrared thermography
Martini et al.
Rheumatology (Oxford) 2002;41:1178-1182.
ABSTRACT
| FULL TEXT
Treatment of Severe Forms of Localized Scleroderma With Oral Corticosteroids: Follow-up Study on 17 Patients
Joly et al.
Arch Dermatol 1994;130:663-664.
ABSTRACT
Fibrotic Skin Diseases: Clinical Presentations, Etiologic Considerations, and Treatment Options
Uitto and Jimenez
Arch Dermatol 1990;126:661-664.
ABSTRACT
|
